about
FES kinases are required for oncogenic FLT3 signalingStructural and functional alterations of FLT3 in acute myeloid leukemiaDownstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implicationsAnimal models of leukemia: any closer to the real thing?An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatmentExpression of the TEL-Syk fusion protein in hematopoietic stem cells leads to rapidly fatal myelofibrosis in miceOptimization of Imidazo[4,5- b ]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid LeukemiaTET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.Receptor Signaling Directs Global Recruitment of Pre-existing Transcription Factors to Inducible ElementsClinical outcome of de novo acute myeloid leukaemia patients with normal cytogenetics is affected by molecular genetic alterations: a concise reviewPRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapyReversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cellsSurvey of activated FLT3 signaling in leukemiaSelective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cellsEvaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancerCloning and expression profile of FLT3 gene during progenitor cell-dependent liver regenerationKnock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse modelThe origin and evolution of mutations in acute myeloid leukemiaGenomic and epigenomic landscapes of adult de novo acute myeloid leukemia.Sunitinib malate for the treatment of solid tumours: a review of current clinical data.H2O2 production downstream of FLT3 is mediated by p22phox in the endoplasmic reticulum and is required for STAT5 signalling.RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.Intra-articular fms-like tyrosine kinase 3 ligand expression is a driving force in induction and progression of arthritis.Successful treatment with low-dose decitabine in acute myelogenous leukemia in elderly patients over 80 years old: Five case reportsFunctions of flt3 in zebrafish hematopoiesis and its relevance to human acute myeloid leukemia.Smac mimetics: implications for enhancement of targeted therapies in leukemiaFLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia.Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles.Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical SignificanceSalvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITDThe Cytokine Flt3-Ligand in Normal and Malignant HematopoiesisThe AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemiaEphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse modelTreatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.Innate immune regulation by STAT-mediated transcriptional mechanisms.Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.Interleukin-3 receptor in acute leukemia.
P2860
Q24297863-AC8704E6-0B46-4349-9674-70B3B307DC09Q24338964-D5A3AD8D-979B-45C3-9616-477C405646D6Q24617091-C588493F-9993-4507-AD25-630F75BBFE10Q27026520-C97B6553-5A4E-41B8-BDA3-E903E9275EDCQ27027207-9179CF4B-AC9B-4943-AC20-C47E45B1088CQ27303848-9445BCE9-1D7C-4612-BC6B-D006F0FDA962Q27674324-6861D780-6FA1-4DAB-A730-BD9ACF891388Q27853009-878D32EF-51FA-4C20-A1D4-C211F6FCCE8EQ28079289-9F083BB7-0D3C-4876-9749-F0737E373A9CQ28301344-8C60004C-8EB9-4F35-AA92-EF82F336960CQ28388468-858D8275-16EE-4DEB-840A-EF457ABBE695Q28477269-07D104B3-324D-4C66-A0FA-B52425028C30Q28477934-096F1FBB-2AEE-42E7-A5B7-DF9B20D1C370Q28486435-8537D64E-DBFC-4355-BC61-119A67A0040BQ28538435-ECADB349-672D-4FCC-B5A8-46F23A3767A9Q28574842-B791DCFA-FA96-443B-8656-919BCC46A375Q28590872-3CF9BEC5-0865-4FF4-87D8-4EF47C5A6C90Q29614630-51C9BF62-3BFD-420A-9735-F6CAAA51C7ECQ29615735-A4A7BAA4-8975-4348-A24D-DA1CF67B1466Q31037756-B3FB940D-3309-4BBB-B777-2C93373770DAQ31074393-E1F0440B-E2EB-49C8-9987-249F4F9194F6Q33306326-1785821B-8A0A-4A57-B32C-5EEA4FE4F33AQ33382375-8951C2A3-37A9-4841-B5C3-2936FB97B52FQ33407141-CCD5FB28-3D8A-41F8-9205-50E3B66A79AAQ33595837-E9ED64E5-1217-4B31-93D4-9C869F384AE2Q33683159-CE93DAB4-0F5C-4E7A-A0AA-1E1C8F628820Q33704528-397E09EF-FA40-48B1-BA86-DF44B1FB38F1Q33737789-02D5CED6-A29A-4AC6-AD33-F4EF2ABB64C4Q33745075-CE68F36A-0DC5-4C18-989A-70D47AB22404Q33778374-D8294FAB-E05C-418B-B97E-C153BC74BFD6Q33798909-EEDE0E2C-9C9C-4415-9802-C44AE64D5378Q33838356-4567FFD2-304B-4938-8C76-698239D48E58Q33895709-915F7EAF-4BE2-4D67-BC00-0C27D6EE1234Q33913329-7C3F19F8-5553-4780-A32C-96430D513365Q33924763-14E9241C-7A81-4DE6-ABA2-C3BB5EA547B1Q34011740-C5888D6C-2F15-46DC-B316-92F27F4F9750Q34055968-EB51C02C-69B4-41C2-89B1-755606AB342CQ34095013-44BE3912-7173-4902-BDCE-A03ED6E5954EQ34113855-3D933E23-1C04-4C6C-AFBC-04136E222532Q34283145-5C7912FC-7B23-4589-A4FE-97DE30D25E63
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The role of FLT3 in haematopoietic malignancies
@ast
The role of FLT3 in haematopoietic malignancies
@en
The role of FLT3 in haematopoietic malignancies
@en-gb
The role of FLT3 in haematopoietic malignancies
@nl
type
label
The role of FLT3 in haematopoietic malignancies
@ast
The role of FLT3 in haematopoietic malignancies
@en
The role of FLT3 in haematopoietic malignancies
@en-gb
The role of FLT3 in haematopoietic malignancies
@nl
prefLabel
The role of FLT3 in haematopoietic malignancies
@ast
The role of FLT3 in haematopoietic malignancies
@en
The role of FLT3 in haematopoietic malignancies
@en-gb
The role of FLT3 in haematopoietic malignancies
@nl
P2860
P3181
P356
P1476
The role of FLT3 in haematopoietic malignancies
@en
P2093
Derek L Stirewalt
Jerald P Radich
P2860
P2888
P304
P3181
P356
10.1038/NRC1169
P407
P577
2003-09-01T00:00:00Z
P6179
1037688311